Jadelle

PreclinicalSmall molecule

FFHI 360

Jadelle is one of 38 small molecule programs targeting Effectiveness. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EffectivenessCompleted

EffectivenessPreclinical

Completed

Competition

Competitive Landscape

73 competitors in Effectiveness

#DrugCompanyPhaseTrials

Kesimpta

Novartis

Phase 3

2 2

Mounjaro

Eli Lilly

Phase 3

1 3

Actos

Takeda

Phase 3

1 4

Nicotine Free Cigarettes

Pfizer

Phase 3

3 5

Botulinum Toxin a

GSK

Phase 3

1 6

Droxia

TTheravia

Phase 2

9 7

Gemzar

Johnson & Johnson

Phase 2

1 8

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 9

Pneumococcal Conjugate Vaccine

Novartis

Phase 3

1 10

Silver Diamine Fluoride

TThe University of Hong Kong

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

Safety,Effectiveness and Acceptability of Sino-implant II in DR

Completed·FFHI 360·N/A·NCT01594632·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Jadelle. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Jadelle compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Jadelle. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — FHI 360 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFHI 360

Jadelle

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News